コンテンツへスキップ
Merck
すべての画像(1)

主要文書

安全性情報

232120

Sigma-Aldrich

cis-Diammineplatinum(II) dichloride

≥98% (HPLC), solid, anti-neoplastic agent, Calbiochem

別名:

Cisplatin, CPDC, DDP, cis-Diaminedichloroplatinum

ログイン組織・契約価格を表示する


About This Item

化学式:
Pt(NH3)2Cl2
CAS番号:
MDL番号:
UNSPSCコード:
12352200
NACRES:
NA.77

製品名

Cisplatin, Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation.

品質水準

詳細

Merck USA index - 14, 2317

アッセイ

≥98% (HPLC)

フォーム

solid

メーカー/製品名

Calbiochem®

保管条件

OK to freeze

yellow

溶解性

PBS with 140 mM NaCl: 1 mg/mL
water with 154 mM NaCl: 1 mg/mL
DMSO: 10 mg/mL

輸送温度

ambient

保管温度

2-8°C

InChI

1S/2Cl.2H3N.Pt/h;;2*1H3;

InChI Key

JFUARQHXOQHNLK-UHFFFAOYSA-N

詳細

A platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation. Reported to sensitize glioma cells to TNF-α-induced apoptosis.

Note: Athough highly soluble in DMSO, Cisplatin is reported to be rendered inactive due to ligand displacement by the nucleophilic sulfur of DMSO. Sodium chloride solution in water (154 mM NaCl with or without 10 mg/ml mannitol) or PBS (with 140 mM NaCl) is recommended for solubilization prior to culture treatment.

生物化学的/生理学的作用

Cell permeable: no
Primary Target
Induces apoptosis in cancer cells
Product does not compete with ATP.
Reversible: no

警告

Toxicity: Toxic & Carcinogenic / Teratogenic (G)

再構成

Unstable in solution; reconstitute just prior to use.

その他情報

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Hall, M.D., et al. 2014. Cancer Res. In press.
Duan, L., et al. 2001. J. Neurooncol.52, 23.
Mese, H., et al. 2000. Cancer Chemother. Pharmacol. 46, 241.
Von Hoff, D.D., and Rozencweig, M. 1979. in Adv. Pharmacol. Chemother.16, 279.

法的情報

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

ピクトグラム

Skull and crossbonesHealth hazard

シグナルワード

Danger

危険有害性の分類

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

ターゲットの組織

Respiratory system

保管分類コード

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

労働安全衛生法名称等を表示すべき危険物及び有害物

名称等を表示すべき危険物及び有害物

労働安全衛生法名称等を通知すべき危険物及び有害物

名称等を通知すべき危険物及び有害物

Jan Code

232120-50MG:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

Jinan Li et al.
Frontiers in molecular neuroscience, 15, 835448-835448 (2022-03-01)
Cisplatin is one of the most widely used chemotherapeutic drugs across the world. However, the serious ototoxic effects, leading to permanent hair cell death and hearing loss, significantly limit the utility of cisplatin. In zebrafish, the functional mechanotransduction channel is
Benjamin P Sharpe et al.
Cell reports. Medicine, 3(6), 100541-100541 (2022-06-23)
The chemotherapy resistance of esophageal adenocarcinomas (EACs) is underpinned by cancer cell extrinsic mechanisms of the tumor microenvironment (TME). We demonstrate that, by targeting the tumor-promoting functions of the predominant TME cell type, cancer-associated fibroblasts (CAFs) with phosphodiesterase type 5
Jiaqi Liu et al.
eLife, 10 (2021-12-18)
Gliomas are highly malignant brain tumors with poor prognosis and short survival. NAD+ has been shown to impact multiple processes that are dysregulated in cancer; however, anti-cancer therapies targeting NAD+ synthesis have had limited success due to insufficient mechanistic understanding.
Mohammed Hafiz Uddin et al.
Frontiers in oncology, 12, 908603-908603 (2022-07-19)
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases. Despite durable responses, almost all patients receiving PARPis ultimately develop resistance and
Hyang Sook Seol et al.
Journal of gynecologic oncology (2023-01-21)
Advanced cervical cancer is still difficult to treat and in the case of recurrent cancer, it is desirable to utilize personalized treatment rather than uniform treatment because the type of recurrence is different for each individual. Therefore, this study aimed

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)